ProCE Banner Activity


Discussing the Next Generation of Predictive Biomarkers and Targeted Therapies in Gastrointestinal Malignancies


Get up to date with this on-demand webcast from a live symposium focused on the latest approaches in using predictive biomarkers to guide treatment for patients with GI cancers.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: March 29, 2023

Expiration: March 28, 2024



John Marshall

John Marshall, MD

Executive Director 
Medstar Hematology/Oncology
Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC

Christopher H. Lieu

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Manish Shah

Manish Shah, MD

Chief, Solid Tumor Services
Bartlett Family Professor of Gastrointestinal Oncology
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from



Elevation Oncology

Merck Sharp & Dohme Corp.

Merus NV

Seagen Inc.

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with gastrointestinal cancers.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in the assessment of predictive biomarkers to guide the individualized treatment of patients with gastrointestinal malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement evidence-based molecular testing in GI cancers, including BRAF V600E, HER2/HER3, BRCA1/2, FGFR2, IDH1, and histology-agnostic markers

  • Plan targeted therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment, available data, and expert recommendations

  • Counsel patients about their tumor molecular profile and how this information will guide therapy decisions

  • Identify patients with GI malignancies eligible for enrollment in ongoing clinical trials of novel biomarker-driven treatment strategies


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

John L. Marshall, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Caris, Indivumed, Merck, Pfizer, Seagen, Taiho.

Christopher H. Lieu, MD: researcher: Merck.

Manish Shah, MD: researcher: Bristol-Myers Squibb, Merck.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 29, 2023, through March 28, 2024:

  1. Create an account or Login at
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.